Introduction: The objective of the present study was to evaluate the safety of retroperitoneoscopic nephrectomy (RN) in obese Japanese patients. Patients and Methods: We retrospectively reviewed 190 consecutive RN procedures performed from May 2002 to May 2006. We divided patients into an obese group (BMI ≥25, n = 54) and a normal group (BMI <24.9, n = 136). Operation time, estimated blood loss, and complications were compared between the two groups. Results: The mean operation time was longer in the obese group than in the normal group (203 vs. 184 min, respectively; p = 0.029). The mean estimated blood loss in the obese and normal groups was 127 and 91 ml, respectively. This difference was not significant (p = 0.39). There was no significant difference in complications and the open conversion rate between the two groups. Conclusions: Although the operation time in obese patients was slightly longer than in non-obese patients, RN in obese patients was safely performed.

Keywords:
Kidney neoplasms, Laparoscope, Retroperitoneoscope, Obesity, Nephrectomy
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.